A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
Copyright © 2013 Wiley Periodicals, Inc..
Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N = 74) or MMUD (N = 40). We compared outcome of MUD versus MMUD patients. There was no difference in the cumulative incidence of grades II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, P = 0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, P = 0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, P = 0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, P = 0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, P = 0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, P = 0.476) and overall survival (MUD: 63% vs. MMUD: 61%, P = 0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
American journal of hematology - 89(2014), 1 vom: 23. Jan., Seite 83-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Devillier, Raynier [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antilymphocyte Serum |
|---|
| Anmerkungen: |
Date Completed 26.03.2014 Date Revised 27.01.2014 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/ajh.23592 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM231537301 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM231537301 | ||
| 003 | DE-627 | ||
| 005 | 20231224090951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.23592 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0771.xml |
| 035 | |a (DE-627)NLM231537301 | ||
| 035 | |a (NLM)24108528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Devillier, Raynier |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2014 | ||
| 500 | |a Date Revised 27.01.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Wiley Periodicals, Inc. | ||
| 520 | |a Conditioning regimen including fludarabine, intravenous busulfan (Bx), and 5 mg/kg total dose of rabbit antithymocyte globulin (r-ATG) (FBx-ATG) results in low incidence of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) from HLA-matched related or unrelated donors (MUD). However, whether this platform produces similar results in the setting of one mismatch unrelated donor (MMUD) Allo-HSCT is not known. We retrospectively analyzed patients aged less than 65 years who were diagnosed with hematological malignancies and received FBx-ATG regimen prior to Allo-HSCT from MUD (N = 74) or MMUD (N = 40). We compared outcome of MUD versus MMUD patients. There was no difference in the cumulative incidence of grades II-IV acute GVHD (MUD: 34% vs. MMUD: 35%, P = 0.918), but MMUD patients developed more grade III-IV acute GVHD (MUD: 5% vs. MMUD: 15%, P = 0.016). The cumulative incidences of overall chronic GVHD (MUD: 33% vs. MMUD: 22%, P = 0.088) and extensive chronic GVHD (MUD: 20% vs. MMUD: 19%, P = 0.594) were comparable. One-year NRM was similar in both groups (MUD: 16% vs. MMUD: 14%, P = 0.292); similarly, progression-free survival (MUD: 59% vs. MMUD: 55%, P = 0.476) and overall survival (MUD: 63% vs. MMUD: 61%, P = 0.762) were not different between both groups. With a median follow up of 24 months, 35 of 74 MUD patients (47%) and 19 of 40 MMUD patients (48%) were free of both disease progression and immunosuppressive treatment. We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antilymphocyte Serum |2 NLM | |
| 650 | 7 | |a Vidarabine |2 NLM | |
| 650 | 7 | |a FA2DM6879K |2 NLM | |
| 650 | 7 | |a Busulfan |2 NLM | |
| 650 | 7 | |a G1LN9045DK |2 NLM | |
| 650 | 7 | |a fludarabine |2 NLM | |
| 650 | 7 | |a P2K93U8740 |2 NLM | |
| 700 | 1 | |a Fürst, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Crocchiolo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a El-Cheikh, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Castagna, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Harbi, Samia |e verfasserin |4 aut | |
| 700 | 1 | |a Granata, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a D'Incan, Evelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Coso, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Chabannon, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Etienne, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Calmels, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Schiano, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Lemarie, Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Stoppa, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Bouabdallah, Reda |e verfasserin |4 aut | |
| 700 | 1 | |a Vey, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Blaise, Didier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 89(2014), 1 vom: 23. Jan., Seite 83-7 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2014 |g number:1 |g day:23 |g month:01 |g pages:83-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.23592 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2014 |e 1 |b 23 |c 01 |h 83-7 | ||